Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical and biotechnology company that frequently issues news related to its generative AI-driven drug discovery platform and internal pipeline of biologic therapeutics. News coverage for Absci often centers on developments in its lead AI-designed antibody programs, platform collaborations, and corporate updates that are relevant to investors and the broader life sciences community.
A major focus of recent Absci news is ABS-201™, an anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia and investigated for endometriosis. Press releases have described preclinical human ex vivo data on hair growth, the design and initiation of the Phase 1/2a HEADLINE trial in androgenetic alopecia, and plans for Phase 2 development in endometriosis. Updates also highlight scientific advisory board appointments, key opinion leader seminars, and partnerships aimed at elevating patient perspectives in hair loss research.
Investors following ABSI news can also expect announcements on pipeline progress for programs such as ABS-101, ABS-301, and ABS-501, as well as drug creation partnerships with pharmaceutical, biotech, technology, and academic organizations. Absci has reported collaborations with cloud and hardware providers to support its AI Drug Creation platform, along with participation in healthcare and biotech investor conferences and major industry events.
This news feed aggregates Absci’s press releases and third-party coverage, including items on clinical trial milestones, scientific data presentations, financing and capital markets activity, and corporate governance changes. Readers interested in ABSI can use this page to monitor how Absci’s AI-enabled platform, internal therapeutic programs, and partnerships evolve over time and to track key events that may shape the company’s scientific and business trajectory.
Absci Corporation (Nasdaq: ABSI) has expanded into the European pharmaceutical market by launching its Innovation Center in Zug, Switzerland. This strategic move aims to enhance its R&D portfolio and drug development pipeline. The company has appointed two senior executives, Christine Lemke and Christian Stegmann, to spearhead its initiatives. Lemke brings extensive experience from major global biopharmaceutical companies, while Stegmann has a strong background in R&D leadership. The Zug Innovation Center positions Absci to leverage European biotech resources and talent, underscoring its commitment to delivering innovative therapies using generative AI.
Absci Corporation (Nasdaq: ABSI), a leader in generative AI drug creation, announced their participation in the 43rd Annual Cowen Health Care Conference. The management team will engage in a panel discussion on March 6 at 1:40 PM PT and a fireside chat on March 8 at 9:50 AM PT. Both sessions will be accessible via a live and archived webcast on the company’s investor relations website. Absci utilizes its Integrated Drug Creation™ platform to enhance drug development, allowing rapid transitions from AI-designed antibodies to lab-validated candidates within weeks. The company aims to revolutionize the delivery of therapeutics globally.
Absci Corporation (Nasdaq: ABSI) has partnered with St. John’s Cancer Institute (SJCI) to accelerate cancer therapy development.
This collaboration utilizes Absci’s Integrated Drug Creation platform and SJCI’s extensive cancer biospecimen database to streamline the identification of new therapeutic candidates.
The initial focus will be on urological and gastrointestinal cancers, aiming to significantly reduce the typical decade-long drug development timeline and high costs.
Experts from both organizations express optimism that this partnership will enhance the discovery of effective cancer treatments.
Absci Corporation (Nasdaq: ABSI) has expanded its Scientific Advisory Board by adding three prominent experts: Dr. Victor Greiff, Dr. Timothy Lu, and Dr. Hubert Truebel, aiming to enhance its leadership in biologic drug creation. Dr. Greiff specializes in in silico antibody design, Dr. Lu focuses on synthetic biology, and Dr. Truebel brings extensive experience in translational medicine. This strategic move aligns with Absci's mission to leverage generative AI and wet lab technologies to expedite drug development. The company intends to innovate faster and improve therapeutic success rates through this strengthened team.
Absci Corporation (Nasdaq: ABSI) announced a significant breakthrough in biotech by using zero-shot generative AI to create and validate de novo antibodies in silico. This advancement could reduce the time for drug leads to enter clinical trials from six years to just 18-24 months while increasing their success probability. Traditionally, drug discovery is costly and lengthy, taking over a decade and more than $1 billion. Absci's innovative approach may unlock treatments for undruggable diseases and enhance biologic drug discovery efficiency.
Absci Corporation (Nasdaq: ABSI) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 12th at 8:15 a.m. PT. The event can be accessed via a live and archived webcast on the company's investor relations website.
Absci is focused on generative AI drug discovery, utilizing deep learning and synthetic biology to create innovative biotherapeutics. Their Integrated Drug Creation™ platform enables the identification of new drug targets and the development of protein-based drugs.
Absci Corporation (Nasdaq: ABSI) announced its participation in the Berenberg Discover AI Seminar on November 29, 2022, at 10:00 a.m. Eastern Time, in New York. The company, a pioneer in generative AI drug creation, will engage in a fireside chat during the event. Absci focuses on drug and target discovery using deep learning AI and synthetic biology to produce innovative protein-based therapeutics. Their Integrated Drug Creation™ platform streamlines the process from identifying drug targets to generating manufacturing cell lines.
Absci Corporation (Nasdaq: ABSI), a leader in generative AI drug creation, announced its participation in the Piper Sandler Healthcare Conference on December 1, 2022, at 8:30 a.m. ET. The presentation will be accessible via a live and archived webcast on the company's investor relations website. Absci utilizes its Integrated Drug Creation™ platform, which combines deep learning AI and synthetic biology, to enhance protein therapeutic development. The company strives to advance medicine through innovative drug discovery.
Absci Corporation (Nasdaq: ABSI) reported strong third-quarter results, showcasing progress in drug discovery through its Merck collaboration. Total revenue reached $2.4 million, up from $1.5 million in Q3 2021, driven by milestones in its non-standard amino acid (nsAA) technology. Operating expenses increased to $27.6 million, including $2.7 million in severance costs. Cash reserves decreased to $181.3 million. The company expects a total cash decrease of approximately $105 million for 2022, refining their prior estimate. Absci continues to prioritize strategic initiatives, projecting sufficient cash into late 2025.
Absci Corporation (Nasdaq: ABSI) announced its participation in the Stifel Healthcare Conference in New York on November 16, 2022, at 4:10 p.m. ET. The company, known for leveraging generative AI and biological data in therapeutic design, will host a fireside chat, accessible via their investor relations website. Absci focuses on drug discovery and the development of protein-based therapeutics using its Integrated Drug Creation™ platform, aiming to enhance the creation of innovative drugs such as Bionic™ proteins.